Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine
Open Access
Abstract
The feline immunodeficiency virus (FIV) vaccine called Fel-O-Vax® FIV is the first commercial FIV vaccine released worldwide for the use in domestic cats against global FIV subtypes (A–E). This vaccine consists of inactivated dual-subtype (A plus D) FIV-infected cells, whereas its prototype vaccine consists of inactivated dual-subtype whole viruses. Both vaccines in experimental trials conferred moderate-to-substantial protection against heterologous strains from homologous and heterologous subtypes. Importantly, a recent case-control field study of Fel-O-Vax-vaccinated cats with outdoor access and ≥3 years of annual vaccine boost, resulted in a vaccine efficacy of 56% in Australia where subtype-A viruses prevail. Remarkably, this protection rate is far better than the protection rate of 31.2% observed in the best HIV-1 vaccine (RV144) trial. Current review describes the findings from the commercial and prototype vaccine trials and compares their immune correlates of protection. The studies described in this review demonstrate the overarching importance of ant-FIV T-cell immunity more than anti-FIV antibody immunity in affording protection. Thus, future efforts in developing the next generation FIV vaccine and the first effective HIV-1 vaccine should consider incorporating highly conserved protective T-cell epitopes together with the conserved protective B-cell epitopes, but without inducing adverse factors that eliminate efficacy.Keywords
This publication has 81 references indexed in Scilit:
- Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine DesignPLOS ONE, 2013
- HIV-1 Vaccine Trials: Evolving Concepts and DesignsThe Open AIDS Journal, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- T Cell Immunity in Acute HIV‐1 InfectionThe Journal of Infectious Diseases, 2010
- Feline leukemia virus immunity induced by whole inactivated virus vaccinationVeterinary Immunology and Immunopathology, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hostsNature Medicine, 2009
- Evolution of feline immunodeficiency virus in Felidae: Implications for human health and wildlife ecologyVeterinary Immunology and Immunopathology, 2008
- Advances in FIV vaccine technologyVeterinary Immunology and Immunopathology, 2008
- Genomic organization, sequence divergence, and recombination of feline immunodeficiency virus from lions in the wildBMC Genomics, 2008